Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation

PLoS Medicine

Volumn 9, Issue 11, 2012, Pages

  Menzies, Nicolas A ^a,b   Cohen, Ted ^a,c   Lin, Hsien Ho ^d   Murray, Megan ^a   Salomon, Joshua A ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL TRANSMISSION; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MATHEMATICAL MODEL; MIXED INFECTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; PREVALENCE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUBERCULOSIS; XPERT TEST;

AFRICA, SOUTHERN; ANTIBIOTICS, ANTITUBERCULAR; CLINICAL LABORATORY TECHNIQUES; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, THEORETICAL; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; REAL-TIME POLYMERASE CHAIN REACTION; RIFAMPIN; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84870266092     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001347     Document Type: Article

References (105)

1. World Health Organization (2011) Global tuberculosis control: WHO report 2011. Geneva: World Health Organization.
2. Obermeyer Z, Abbott-Klafter J, Murray CJ, (2008) Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS ONE 3: e1721 doi:10.1371/journal.pone.0001721.
3. Denkinger CM, Pai M, (2011) Point-of-care tuberculosis diagnosis: are we there yet? Lancet Infect Dis 12: 169-170.
4. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
5. Elliott AM, Halwiindi B, Hayes RJ, Luo N, Tembo G, et al. (1993) The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 96: 1-11.
6. Getahun H, Harrington M, O'Brien R, Nunn P, (2007) Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369: 2042-2049.
7. Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, et al. (2008) Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 47: 487-495.
8. Van Deun A, Martin A, Palomino JC, (2010) Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 14: 131-140.
9. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, et al. (2011) Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 24: 314-350.
10. Tuberculosis Division (2005) Tuberculosis bacteriology-priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis 9: 355-361.
11. Farmer P, Bayona J, Becerra M, Furin J, Henry C, et al. (1998) The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 2: 869-876.
12. Meintjes G, Schoeman H, Morroni C, Wilson D, Maartens G, (2008) Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis 8: 72.
13. Van Rie A, Enarson D, (2006) XDR tuberculosis: an indicator of public-health negligence. Lancet 368: 1554-1556.
14. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, et al. (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363: 1005-1015.
15. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495-1505.
16. Helb D, Jones M, Story E, Boehme C, Wallace E, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48: 229-237.
17. Theron G, Peter J, van Zyl-Smit R, Mishra H, Streicher E, et al. (2011) Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 184: 132-140.
18. Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, et al. (2011) Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay-a clinical validation study. PLoS ONE 6: e20458 doi:10.1371/journal.pone.0020458.
19. Selibas K, Hanrahan C, Deery C, Dansey H, Clouse K, et al. (2012) TB suspects with negative initial Xpert [abstract]. 3rd South African Tuberculosis Conference; 12-15 June 2012; Durban, South Africa.
20. World Health Organization (2010) Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Geneva: World Health Organization.
21. World Health Organization (2012) WHO monitoring of Xpert MTB/RIF roll-out: orders of GeneXperts and Xpert MTB/RIF cartridges [database]. Available: http://www.stoptb.org/wg/gli/assets/documents/map/1/atlas.html. Accessed 4 September 2012. Geneva: World Health Organization.
22. Mirzayev F (2012) Current dynamics in the Xpert MTB/RIF assay pricing mechanisms [abstract]. Xpert MTB/RIF Early Implementers Meeting; 18-19 April 2012; Annecy, France. Geneva: World Health Organization.
23. Cepheid Pharmaceuticals (2012 Aug 6) Cepheid announces first phase of Xpert MTB/RIF buy-down for high burden developing countries. Sunnyvale (California): Cepheid Pharmaceuticals.
24. Dowdy DW, Cattamanchi A, Steingart KR, Pai M, (2011) Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 8: e1001063 doi:10.1371/journal.pmed.1001063.
25. Evans CA, (2011) GeneXpert-a game-changer for tuberculosis control? PLoS Med 8: e1001064 doi:10.1371/journal.pmed.1001064.
26. Kirwan DE, Cardenas MK, Gilman RH, (2012) Rapid implementation of new tb diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF? Am J Trop Med Hyg 87: 197-201.
27. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, et al. (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8: e1001067 doi:10.1371/journal.pmed.1001067.
28. Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, et al. (2011) Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8: e1001061 doi:10.1371/journal.pmed.1001061.
29. Trebucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, et al. (2011) Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 15: 1567-1572.
30. Van Rie A, Mellet K, John MA, Scott L, Page-Shipp L, et al. (2012) False-positive rifampicin resistance on Xpert(R) MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 16: 206-208.
31. Ramsay A, Steingart KR, Pai M, (2010) Assessing the impact of new diagnostics on tuberculosis control. Int J Tuberc Lung Dis 14: 1506-1507.
32. Theron G, Pooran A, Peter J, van Zyl-Smit R, Kumar Mishra H, et al. (2012) Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? Eur Respir J 40: 161-168.
33. World Health Organization (2011) Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how-to'. Geneva: World Health Organization.
34. Peltzer K, Matseke G, Mzolo T, Majaja M, (2009) Determinants of knowledge of HIV status in South Africa: results from a population-based HIV survey. BMC Public Health 9: 174.
35. Baltussen R, Floyd K, Dye C, (2005) Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331: 1364.
36. Cohen T, Lipsitch M, Walensky RP, Murray M, (2006) Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 103: 7042-7047.
37. Dowdy DW, Chaisson RE, (2009) The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ 87: 296-304.
38. Dye C, Garnett GP, Sleeman K, Williams BG, (1998) Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352: 1886-1891.
39. Dye C, Williams BG, (2000) Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A 97: 8180-8185.
40. Murray CJ, Salomon JA, (1998) Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A 95: 13881-13886.
41. Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sanchez MS, et al. (2006) Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med 3: e273 doi:10.1371/journal.pmed.0030273.
42. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, et al. (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 326: 231-235.
43. Shafer RW, Singh SP, Larkin C, Small PM, (1995) Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in an immunocompetent patient. Tuber Lung Dis 76: 575-577.
44. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, et al. (1999) Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 13: 501-507.
45. Manosuthi W, Tantanathip P, Chimsuntorn S, Eampokarap B, Thongyen S, et al. (2010) Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. Int J Infect Dis 14: e1013-e1017.
46. van der Sande MA, Schim van der Loeff MF, Bennett RC, Dowling M, Aveika AA, et al. (2004) Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 18: 1933-1941.
47. Adam MA, Johnson LF, (2009) Estimation of adult antiretroviral treatment coverage in South Africa. S Afr Med J 99: 661-667.
48. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
49. Stover J, Bollinger L, Avila C, (2011) Estimating the impact and cost of the WHO 2010 recommendations for antiretroviral therapy. AIDS Res Treat 2011: 738271.
50. UNAIDS Reference Group on Estimates, Modelling and Projections (2011) Technical meeting to review Spectrum 2011 and considering potential bias in DHS and ANC data. Geneva: Joint United Nations Programme on HIV/AIDS.
51. Dowdy DW, O'Brien MA, Bishai D, (2008) Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12: 1021-1029.
52. Poole D, Raftery AE, (2000) Inference for deterministic simulation models: the Bayesian melding approach. J Am Stat Assoc 95: 452.
53. Raftery AE, Givens GH, Zeh JE, (1995) Inference from a deterministic population dynamics model for bowhead whales. J Am Stat Assoc 90: 402-430.
54. Alkema L, Raftery AE, Brown T, (2008) Bayesian melding for estimating uncertainty in national HIV prevalence estimates. Sex Transm Infect 84: i11-i16.
55. Alkema L, Raftery AE, Clark SJ, (2007) Probabilistic projections of HIV prevalence using Bayesian melding. Ann Appl Stat 1: 229-248.
56. Brown T, Bao L, Raftery AE, Salomon JA, Baggaley RF, et al. (2010) Modelling HIV epidemics in the antiretroviral era: the UNAIDS Estimation and Projection package 2009. Sex Transm Infect 86 (Suppl 2) (): ii3-ii10.
57. World Health Organization (2011) Tuberculosis (TB) [database]. Available: http://www.who.int/tb/country/data/download/en/index.html. Accessed 30 September 2011. Geneva: World Health Organization.
58. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization.
59. Rubin D (1988) Using the SIR algorithm to simulate posterior distributions. In: Bernardo JM, DeGroot MH, Lindley DV, Smith AFM, editors. Bayesian statistics 3. Oxford: Oxford University Press. pp. 395-402.
60. Joint United Nations Programme on HIV/AIDS (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Geneva: Joint United Nations Programme on HIV/AIDS.
61. World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2006 revision. Geneva: World Health Organization.
62. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 revision. Geneva: World Health Organization.
63. World Health Organization (2011) Global price reporting mechanism for HIV, tuberculosis and malaria. Available: http://www.who.int/hiv/amds/gprm/en/. Accessed 21 May 2011. Geneva: World Health Organization.
64. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, et al. (2012) The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE 7: e36966 doi:10.1371/journal.pone.0036966.
65. Schnippel K, Meyer-Rath G, Long L, Macleod W, Sanne I, et al. (2012) Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 17: 1142-1151.
66. Murray CJL, Lopez AD (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (Massachusetts): Harvard University Press.
67. World Health Organization (2004) Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva: World Health Organization.
68. Tan Torres T, Baltussen R, Adam T, Hutubessy R, Acharya A, et al. (2003) Making choices in health: WHO guide to cost effectiveness analysis. Geneva: World Health Organization.
69. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258.
70. Hutubessy R, Chisholm D, Edejer TT, (2003) Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1: 8.
71. Iman RL, Helton JC, Campbell JE, (1981) An approach to sensitivity analysis of computer models: part I-introduction, input variable selection and preliminary variable assessment. J Qual Technol 13: 174-183.
72. Iman RL, Helton JC, Campbell JE, (1981) An approach to sensitivity analysis of computer models: part II-ranking of input variables, response surface validation, distribution effect, and technique synopsis variable assessment. J Qual Technol 13: 232-240.
73. World Bank (2011) World development indicators 2011. Washington (District of Columbia): World Bank.
74. National Health Laboratory Service (2012) Xpert testing algorithm. South Africa: National Health Laboratory Service.
75. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, et al. (2010) Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 107: 19485-19489.
76. Schnippel K, Rosen S, Shearer K, Martinson N, Long L, et al. (2012) The cost of inpatient treatment for multi-drug resistant tuberculosis in South Africa [abstract]. International AIDS Economics Network 7th AIDS & Economics Pre-Conference; 22-27 July 2012; Washington, District of Columbia, US.
77. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, et al. (2011) Rapid diagnosis of tuberculosis with the Xpert MTB/rif assay in high burden countries: a cost-effectiveness analysis. PLoS Med 8: e1001120 doi:10.1371/journal.pmed.1001120.
78. Andrews JR, Lawn SD, Rusu C, Wood R, Noubary F, et al. (2012) The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 26: 987-995.
79. Rachow A, Clowes P, Saathoff E, Mtafya B, Michael E, et al. (2012) Increased and expedited case detection by Xpert MTB/RIF assay in childhood tuberculosis: a prospective cohort study. Clin Infect Dis 54: 1388-1396.
80. Zar HJ, Workman L, Isaacs W, Munro J, Black F, et al. (2012) Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 55: 1088-1095.
81. Dye C, Williams BG, (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5: 653-662.
82. Frieden T (2004) Toman's tuberculosis: case detection, treatment and monitoring: questions and answers, 2nd edition. Geneva: World Health Organization.
83. Levy H, Feldman C, Sacho H, van der Meulen H, Kallenbach J, et al. (1989) A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest 95: 1193-1197.
84. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE, (2008) Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 105: 11293-11298.
85. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, et al. (2012) AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 54: 714-723.
86. Badri M, Lawn SD, Wood R, (2006) Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 368: 1254-1259.
87. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
88. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, et al. (2007) Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21: 1185-1197.
89. Phillips A, Pezzotti P, Collaboration Cascade, (2004) Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 18: 51-58.
90. When To Start Consortium (2009) Sterne JA, May M, Costagliola D, de Wolf F, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363.
91. Albert H, (2004) Economic analysis of the diagnosis of smear-negative pulmonary tuberculosis in South Africa: incorporation of a new rapid test, FASTPlaqueTB, into the diagnostic algorithm. Int J Tuberc Lung Dis 8: 240-247.
92. Floyd K, Skeva J, Nyirenda T, Gausi F, Salaniponi F, (2003) Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi. Int J Tuberc Lung Dis 7: S29-S37.
93. Hausler HP, Sinanovic E, Kumaranayake L, Naidoo P, Schoeman H, et al. (2006) Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 84: 528-536.
94. Hudson CP, Wood R, Maartens G, (2000) Diagnosing HIV-associated tuberculosis: reducing costs and diagnostic delay. Int J Tuberc Lung Dis 4: 240-245.
95. Nganda B, Wang'ombe J, Floyd K, Kangangi J, (2003) Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Machakos District, Kenya. Int J Tuberc Lung Dis 7: S14-S20.
96. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, et al. (2011) Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med 183: 1103-1111.
97. Suarez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359: 1980-1989.
98. van Cleeff MR, Kivihya-Ndugga LE, Meme H, Odhiambo JA, Klatser PR, (2005) The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis 5: 111.
99. Resch SC, Salomon JA, Murray M, Weinstein MC, (2006) Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3: e241 doi:10.1371/journal.pmed.0030241.
100. Adam T, Evans DB, Murray CJ, (2003) Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 1: 3.
101. Bikilla AD, Jerene D, Robberstad B, Lindtjorn B, (2009) Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. Cost Eff Resour Alloc 7: 6.
102. Bratt JH, Torpey K, Kabaso M, Gondwe Y, (2011) Costs of HIV/AIDS outpatient services delivered through Zambian public health facilities. Trop Med Int Health 16: 110-118.
103. Harling G, Wood R, (2007) The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 45: 348-354.
104. Menzies NA, Berruti AA, Berzon R, Filler S, Ferris R, et al. (2011) The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 25: 1753-1760.
105. Rosen S, Long L, Sanne I, (2008) The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health 13: 1005-1015.